Management of HBV Infection During Immunosuppressive Treatment
2009
Management of HBV Infection During Immunosuppressive Treatment
publication
Evidence: moderate
Author Information
Author(s): Marzano Alfredo
Primary Institution: San Giovanni Battista Hospital, Turin, Italy
Conclusion
A rational approach to managing hepatitis B virus (HBV) in immunocompromised patients includes screening, antiviral treatment for active carriers, and prophylaxis for inactive carriers.
Supporting Evidence
- Two billion people are overt carriers of HBV worldwide, with 360 million suffering from chronic infection.
- Over 520,000 die each year from HBV-related complications.
- Immunosuppression can lead to HBV reactivation, which complicates treatment and survival.
Takeaway
This study talks about how to take care of people with hepatitis B who are getting treatments that weaken their immune system, like chemotherapy. It suggests checking for the virus and using medicine to prevent problems.
Limitations
The literature on hepatitis B in immunocompromised patients is heterogeneous and mainly refers to the pre-antivirals era, which complicates interpretation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website